TransDigm price target raised to $1,200 from $1,113 at UBS

UBS analyst Gavin Parsons raised the firm’s price target on TransDigm to $1,200 from $1,113 and keeps a Neutral rating on the shares. While UBS sees TransDigm as a high quality consistent compounder with a unique business model, executing well within healthy end-markets, with meaningful dry powder optionality, this looks largely priced in, the analyst tells investors in a research note.